Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up After Analyst Upgrade

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) gapped up before the market opened on Thursday after Oppenheimer raised their price target on the stock from $26.00 to $28.00. The stock had previously closed at $10.61, but opened at $11.53. Oppenheimer currently has an outperform rating on the stock. Astria Therapeutics shares last traded at $10.67, with a volume of 27,733 shares traded.

Several other research firms have also issued reports on ATXS. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. TD Cowen began coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $25.60.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATXS. RA Capital Management L.P. acquired a new position in shares of Astria Therapeutics during the 1st quarter worth about $62,115,000. FMR LLC raised its position in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Artal Group S.A. acquired a new position in shares of Astria Therapeutics during the 1st quarter worth about $12,445,000. Vestal Point Capital LP raised its holdings in Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Astria Therapeutics in the 2nd quarter valued at about $6,142,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Down 4.9 %

The company has a market cap of $569.33 million, a price-to-earnings ratio of -4.39 and a beta of 0.71. The stock’s fifty day simple moving average is $11.44 and its 200 day simple moving average is $10.60.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, analysts predict that Astria Therapeutics, Inc. will post -1.68 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.